2024
Lung-MAP Next Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)
Kozono D, Hua X, Wu M, Tolba K, Waqar S, Dragnev K, Cheng H, Hirsch F, Mack P, Gray J, Kelly K, Borghaei H, Herbst R, Gandara D, Redman M. Lung-MAP Next Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). Journal Of Thoracic Oncology 2024 PMID: 39111731, DOI: 10.1016/j.jtho.2024.07.024.Peer-Reviewed Original ResearchNext generation sequencingLung SqCCNext generation sequencing dataAdvanced squamous cell lung cancerGene set analysisSquamous cell lung cancerAssociated with poor survivalFalse discovery rate <Squamous cell cancerCancer-related genesCell lung cancerCox proportional hazards modelsOxidative stress responseNGS datasetsUncharacterized genesLung cancer subtypesNon-overlapping setsCancer Genome AtlasProportional hazards modelGeneration sequencingGenetic variantsUncharacterized roleCell cancerTreatment resistanceGene alterations
2021
MA11.10 Lung Master Protocol (Lung-MAP) Next Generation Sequencing Analysis of Advanced Squamous Cell Cancers (SWOG S1400)
Kozono D, Hua X, Wu M, Tolba K, Waqar S, Dragnev K, Cheng H, Hirsch F, Mack P, Kelly K, Herbst R, Gandara D, Redman M. MA11.10 Lung Master Protocol (Lung-MAP) Next Generation Sequencing Analysis of Advanced Squamous Cell Cancers (SWOG S1400). Journal Of Thoracic Oncology 2021, 16: s176-s177. DOI: 10.1016/j.jtho.2021.01.254.Peer-Reviewed Original Research
2019
Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).
Waqar S, Redman M, Arnold S, Hirsch F, Mack P, Schwartz L, Gandara D, Stinchcombe T, Leighl N, Ramalingam S, Tanna S, Raddin R, Minichiello K, Kelly K, Bradley J, Herbst R, Papadimitrakopoulou V. Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753). Journal Of Clinical Oncology 2019, 37: 9075-9075. DOI: 10.1200/jco.2019.37.15_suppl.9075.Peer-Reviewed Original ResearchProgression-free survivalOverall survivalCohort 1Interim analysisLung squamous cell cancerAdequate organ functionDisease control rateMedian overall survivalPhase II studySquamous cell cancerDuration of responseEvaluable patientsG3 eventsImmunotherapy exposureRECIST 1.1Stable diseasePrimary endpointSecondary endpointsUnacceptable toxicityAdverse eventsII studyHepatic involvementCell cancerPositive tumorsControl rate
2012
Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck.
Baumgart M, Acevedo-Gadea C, Wang Z, Buta E, Davies M, Deshpande H, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2012, 30: 5532-5532. DOI: 10.1200/jco.2012.30.15_suppl.5532.Peer-Reviewed Original ResearchPoor prognostic factorSquamous cell carcinomaExtracapsular extensionOral cavityOverall survivalPrognostic factorsCell carcinomaIndependent poor prognostic factorNeck squamous cell carcinomaCox proportional hazards modelSignificant OS differenceSquamous cell cancerProportional hazards modelPrognostic impactSurveillance EpidemiologyCell cancerPoor outcomeKaplan-MeierECE statusOS differenceAJCC manualEligibility criteriaHazards modelPrimary siteSurvival curves
2003
Erlotinib (Tarceva): An update on the clinical trial program
Herbst RS. Erlotinib (Tarceva): An update on the clinical trial program. Seminars In Oncology 2003, 30: 34-46. PMID: 12840799, DOI: 10.1016/s0093-7754(03)70013-x.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerAdvanced non-small cell lung cancerPhase II monotherapy trialsNeck squamous cell cancerUse of erlotinibAntitumor activitySingle-agent chemotherapyPhase III trialsClinical trial programSquamous cell cancerSimilar patient populationsSubstantial antitumor activityHuman tumor xenograftsMonotherapy trialsEpidermal growth factor receptor tyrosine kinaseIII trialsCell cancerPatient populationPancreatic cancerOvarian cancerPreclinical studiesGrowth factor receptor tyrosine kinaseTumor xenograftsHead and neck cancer
Kies M, Herbst R. Head and neck cancer. 2003, 207-216. DOI: 10.1017/cbo9780511527081.025.Peer-Reviewed Original ResearchSquamous cell cancerNeck malignanciesCell cancerNeck cancerTobacco useNeck squamous cell cancerIndependent risk factorEpstein-Barr virusFloor of mouthConsumption of fruitsDose-response relationshipSynergistic carcinogenic effectUncommon headAdvanced diseaseMost patientsMedian ageAnnual incidenceViral exposureCommon cancerRisk factorsTreatment outcomesIntroduction HeadBuccal mucosaNasopharyngeal carcinomaOral cavity